The HER2-Binding Affibody Molecule (ZHER2:342)2 Increases Radiosensitivity in SKBR-3 Cells

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Ekerljung, Lina ^a   Lennartsson, Johan ^b   Gedda, Lars ^a,c  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c Swedish Radiation Protection Authority   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; HER2 BINDING AFFIBODY MOLECULE; UNCLASSIFIED DRUG;

ARTICLE; CELL STIMULATION; CELL STRAIN; CELL SURVIVAL; CLONOGENESIS; CONTROLLED STUDY; DIMERIZATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IONIZING RADIATION; IRRADIATION; PROTEIN PHOSPHORYLATION; RADIOSENSITIVITY; SKBR 3 CELL;

CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; KINETICS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN MULTIMERIZATION; RADIATION TOLERANCE; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS;

EID: 84869110616     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049579     Document Type: Article

References (28)

1. Slamon DJ, Clark GM, Wong SG, (1987) Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182.
2. Chen JS, Lan K, Hung MC, (2003) Strategies to target HER2/neu overexpression for cancer therapy. Drug Resistance Updates 6: 129-136.
3. Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, et al. (2003) The HER-2/neu gene and protein in breast cancer 2003: Biomarker and target of therapy. Oncologist 8: 307-325.
4. Graus-Porta D, Beerli RR, Daly JM, Hynes NE, (1997) ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO Journal 16: 1647-1655.
5. Marmor MD, Skaria KB, Yarden Y, (2004) Signal transduction and oncogenesis by ErbB/HER receptors. International Journal of Radiation Oncology Biology Physics 58: 903-913.
6. Nygren PÅ, (2008) Alternative binding proteins: Affibody binding proteins developed from a small three-helix bundle scaffold. FEBS Journal 275: 2668-2676.
7. Baum RP, Prasad V, Muller D, Schuchardt C, Orlova A, et al. (2010) Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules. J Nucl Med 51: 892-897.
8. Ekerljung L, Lindborg M, Gedda L, Frejd FY, Carlsson J, et al. (2008) Dimeric HER2-specific affibody molecules inhibit proliferation of the SKBR-3 breast cancer cell line. Biochem Biophys Res Commun 377: 489-494.
9. Björkelund H, Gedda L, Barta P, Malmqvist M, Andersson K, (2011) Gefitinib Induces Epidermal Growth Factor Receptor Dimers Which Alters the Interaction Characteristics with 125I-EGF. PLoS ONE 6: e24739.
10. Yang S, Raymond-Stintz MA, Ying W, Zhang J, Lidke DS, et al. (2007) Mapping ErbB receptors on breast cancer cell membranes during signal transduction. Journal of Cell Science 120: 2763-2773.
11. Aguilar Z, Akita RW, Finn RS, Ramos BL, Pegram MD, et al. (1999) Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells. Oncogene 18: 6050-6062.
12. Björke H, Andersson K, (2006) Measuring the affinity of a radioligand with its receptor using a rotating cell dish with in situ reference area. Applied Radiation and Isotopes 64: 32-37.
13. Ekerljung L, Steffen AC, Carlsson J, Lennartsson J, (2006) Effects of HER2-binding affibody molecules on intracellular signaling pathways. Tumor Biology 27: 201-210.
14. Johansson L, Nilsson K, Carlsson J, (1981) Radiation effects on cultured human lymphoid cells. Analysis using the growth extrapolation method. Acta Radiologica Oncology Radiation Therapy Physics and Biology 20: 51-59.
15. Liang K, Lu Y, Jin W, Ang KK, Milas L, et al. (2003) Sensitization of breast cancer cells to radiation by trastuzumab. Molecular Cancer Therapeutics 2: 1113-1120.
16. Cao N, Li S, Wang Z, Ahmed KM, Degnan ME, et al. (2009) NF-κB-Mediated HER2 Overexpression in Radiation-Adaptive Resistance. Radiation Research 171: 9-21.
17. Orlova A, Magnusson M, Eriksson TLJ, Nilsson M, Larsson B, et al. (2006) Tumor imaging using a picomolar affinity HER2 binding Affibody molecule. Cancer Research 66: 4339-4348.
18. Holbro T, Hynes NE (2004) ErbB Receptors: Directing Key Signaling Networks Throughout Life. 195-217.
19. Ignatoski KMW, LaPointe AJ, Radany EH, Ethier SP, (1999) erbB-2 Overexpression in Human Mammary Epithelial Cells Confers Growth Factor Independence. Endocrinology 140: 3615-3622.
20. Guy PM, Platko JV, Cantley LC, Cerione RA, Carraway Iii KL, (1994) Insect cell-expressed p180(erbB3) possesses an impaired tyrosine kinase activity. Proceedings of the National Academy of Sciences of the United States of America 91: 8132-8136.
21. Steffen AC, Göstring L, Tolmachev V, Palm S, Stenerlöw B, et al. (2008) Differences in radiosensitivity between three HER2 overexpressing cell lines. European Journal of Nuclear Medicine and Molecular Imaging 35: 1179-1191.
22. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, et al. (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. The Lancet Oncology 11: 21-28.
23. Meyn RE, Munshi A, Haymach JV, Milas L, Ang KK, (2009) Receptor signaling as a regulatory mechanism of DNA repair. Radiotherapy and Oncology 92: 316-322.
24. Lennartsson J, Carlsson J, Stenerlow B, (2006) Targeting the Epidermal Growth Factor Receptor Family in Radionuclide Therapy of Tumors-Signal Transduction and DNA Repair. Letters in Drug Design & Discovery 3: 357-368.
25. Nordberg E, Ekerljung L, Sahlberg SH, Carlsson J, Lennartsson J, et al. (2010) Effects of an EGFR-binding affibody molecule on intracellular signaling pathways. International journal of oncology 36.
26. Garrett TPJ, McKern NM, Lou M, Elleman TC, Adams TE, et al. (2002) Crystal Structure of a Truncated Epidermal Growth Factor Receptor Extracellular Domain Bound to Transforming Growth Factor alpha. Cell 110: 763-773.
27. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, et al. (2003) Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421: 756-760.
28. Eigenbrot C, Ultsch M, Dubnovitsky A, Abrahmsén L, Härd T, (2010) Structural basis for high-affinity HER2 receptor binding by an engineered protein. Proceedings of the National Academy of Sciences 107: 15039-15044.